Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
Xiaoli Wang, Raajit K. Rampal, Cing Siang Hu, Joseph Tripodi, Noushin Farnoud, Bruce Petersen, Michael R. Rossi, Minal Patel, Erin McGovern, Vesna Najfeld, Camelia Iancu-Rubin, Min Lu, Andrew Davis, Marina Kremyanskaya, Rona Singer Weinberg, John Mascarenhas, Ronald Hoffman
Xiaoli Wang, Raajit K. Rampal, Cing Siang Hu, Joseph Tripodi, Noushin Farnoud, Bruce Petersen, Michael R. Rossi, Minal Patel, Erin McGovern, Vesna Najfeld, Camelia Iancu-Rubin, Min Lu, Andrew Davis, Marina Kremyanskaya, Rona Singer Weinberg, John Mascarenhas, Ronald Hoffman
View: Text | PDF
Research Article Oncology Stem cells

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase

  • Text
  • PDF
Abstract

Chronic myeloproliferative neoplasms (MPN) frequently evolve to a blast phase (BP) that is almost uniformly resistant to induction chemotherapy or hypomethylating agents. We explored the functional properties, genomic architecture, and cell of origin of MPN-BP initiating cells (IC) using a serial NSG mouse xenograft transplantation model. Transplantation of peripheral blood mononuclear cells (MNC) from 7 of 18 patients resulted in a high degree of leukemic cell chimerism and recreated clinical characteristics of human MPN-BP. The function of MPN-BP ICs was not dependent on the presence of JAK2V617F, a driver mutation associated with the initial underlying MPN. By contrast, multiple MPN-BP IC subclones coexisted within MPN-BP MNCs characterized by different myeloid malignancy gene mutations and cytogenetic abnormalities. MPN-BP ICs in 4 patients exhibited extensive proliferative and self-renewal capacity, as demonstrated by their ability to recapitulate human MPN-BP in serial recipients. These MPN-BP IC subclones underwent extensive continuous clonal competition within individual xenografts and across multiple generations, and their subclonal dynamics were consistent with functional evolution of MPN-BP IC. Finally, we show that MPN-BP ICs originate from not only phenotypically identified hematopoietic stem cells, but also lymphoid-myeloid progenitor cells, which were each characterized by differences in MPN-BP initiating activity and self-renewal capacity.

Authors

Xiaoli Wang, Raajit K. Rampal, Cing Siang Hu, Joseph Tripodi, Noushin Farnoud, Bruce Petersen, Michael R. Rossi, Minal Patel, Erin McGovern, Vesna Najfeld, Camelia Iancu-Rubin, Min Lu, Andrew Davis, Marina Kremyanskaya, Rona Singer Weinberg, John Mascarenhas, Ronald Hoffman

×

Figure 1

MPN-BP ICs are capable of engrafting and recapitulating MPN-BP in NSG mice.

Options: View larger image (or click on image) Download as PowerPoint
MPN-BP ICs are capable of engrafting and recapitulating MPN-BP in NSG mi...
(A and B) Human CD45+ (hCD45+) cell chimerism (A) and the level of immature myeloid cells as indicated by percentage of hCD34+ and hCD45dimCD33+ cells in the BM, spleen, and PB of NSG mice receiving PB CD3+ cell–depleted MNCs from the 18 patients with MPN-AP/BP or normal CB CD34+ cells from 3 individual donors. Each symbol represents the mean from 2–4 different mice receiving one individual sample. (C) BM and spleen sections 8 weeks after the transplantation with primary samples from Pt 2 were stained with H&E and an anti-hCD34 mAb. Scale bars: 50 μm. (D) Fold increase in spleen weight of mice belonging to Group 1 and Group 2 relative to control mice. Control mice received PBS alone. For Group 1 (n = 7) samples, results were obtained from analyses of mice that were sacrificed 7 weeks (Pt 5), 8–9 weeks (Pts 2, 3, 4), and 16–18 weeks (Pts 1, 6, 7) after transplantation. For Group 2 (n = 11) samples, mice were sacrificed 4–7 months after the transplantation. *P < 0.05, **P < 0.01, ***P < 0.001, §P=0.05 by ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts